Multivalent Ligands to Control Stem Cell Fate

控制干细胞命运的多价配体

基本信息

  • 批准号:
    9318607
  • 负责人:
  • 金额:
    $ 32.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-01 至 2019-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The objective of the proposed work is to design potent multivalent ligands that influence the differentiation of adult neural stem cells (NSCs) and human pluripotent stem cells (hPSCs) based on a biomimetic strategy - multivalency. Cellular signal transduction can often begin with the multivalent binding of ligands, either secreted or cell-surface tethered, to target cell receptors, leading to receptor clustering. The capacity to control multivalent interactions and thereby modulate key signaling events within living systems is, however, currently very limited. While antibody-induced ligand or receptor clustering has been achieved, this method is not well- controlled, efficient, or readily reproducible. Intracellulr targets can be clustered by the small-molecule dependent dimerization of repeated inducible dimerizing domains, but this approach involves overexpressing fusion proteins and is not readily applicable for endogenous ligands or receptors. The use of synthetic multivalent ligands is a promising approach to control and to elucidate fundamental mechanisms in cellular signaling. If such multivalent ligands could be designed to activate key signaling pathways and thereby control stem cell fate in vitro and in vivo, they could serve as both powerful biological tools and as potent therapeutics. The first aim of the proposed work is to harness multivalent ephrin conjugates to study mechanisms by which Eph-ephrin signaling regulates cell fate decisions in neural stem cells and pluripotent stem cells. Within this aim, we will conduct a structure-function analysis of ephrin multivalency in signaling and stem cell differentiation, as well as engineer peptide-based multivalent ligands for potent activation of Eph-ephrin signaling in vitro and in vivo. Our second aim is to determine whether multivalent conjugates can be engineered to activate Wnt signaling in NSCs, which will be achieved with a combination of engineering peptide-based multivalent ligands and characterizing their signaling properties in vitro and in vivo. We anticipate that the resulting multivalent ephrin and Wnt ligands will serve as potent bioactive materials for controlling stem cell fate decisions, a capability that would be significan for mechanistic investigations in stem cell and developmental biology in vitro and in vivo, as well as for applications including enhanced cell culture systems, pharmacology and toxicology screens, and regenerative medicine approaches to restore organ function.
描述(由申请人提供):拟议工作的目标是设计有效的多价配体,影响成体神经干细胞(NSCs)和神经干细胞的分化

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ravi S. Kane其他文献

Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice
多价 S2 亚单位疫苗为雌性小鼠提供了针对第 1 群沙贝科病毒的广泛保护
  • DOI:
    10.1038/s41467-025-55824-y
  • 发表时间:
    2025-01-07
  • 期刊:
  • 影响因子:
    15.700
  • 作者:
    Peter J. Halfmann;Raj S. Patel;Kathryn Loeffler;Atsuhiro Yasuhara;Lee-Ann Van De Velde;Jie E. Yang;Jordan Chervin;Chloe Troxell;Min Huang;Naiying Zheng;Elizabeth R. Wright;Paul G. Thomas;Patrick C. Wilson;Yoshihiro Kawaoka;Ravi S. Kane
  • 通讯作者:
    Ravi S. Kane
Enzyme-based formulations for decontamination: current state and perspectives
  • DOI:
    10.1007/s00253-013-4797-x
  • 发表时间:
    2013-03-10
  • 期刊:
  • 影响因子:
    4.300
  • 作者:
    Navdeep Grover;Cerasela Zoica Dinu;Ravi S. Kane;Jonathan S. Dordick
  • 通讯作者:
    Jonathan S. Dordick
Facile generation of drug-like conformational antibodies specific for amyloid fibrils
针对淀粉样纤维的类药物构象抗体的简便生成
  • DOI:
    10.1038/s41589-025-01881-9
  • 发表时间:
    2025-04-29
  • 期刊:
  • 影响因子:
    13.700
  • 作者:
    Alec A. Desai;Jennifer M. Zupancic;Hanna Trzeciakiewicz;Julia E. Gerson;Kelly N. DuBois;Mary E. Skinner;Lisa M. Sharkey;Nikki McArthur;Sean P. Ferris;Nemil N. Bhatt;Emily K. Makowski;Matthew D. Smith;Hongwei Chen;Jie Huang;Cynthia Jerez;Yun-Huai Kuo;Ravi S. Kane;Nicholas M. Kanaan;Henry L. Paulson;Peter M. Tessier
  • 通讯作者:
    Peter M. Tessier

Ravi S. Kane的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ravi S. Kane', 18)}}的其他基金

Engineering Protein Antigens and their Presentation from Multivalent Scaffolds
工程蛋白质抗原及其从多价支架的呈现
  • 批准号:
    10582942
  • 财政年份:
    2023
  • 资助金额:
    $ 32.81万
  • 项目类别:
Design and Evolution of Polyvalent Domain Antibodies Specific for Tau Aggregates
Tau 聚集体特异性多价域抗体的设计和进化
  • 批准号:
    10585480
  • 财政年份:
    2018
  • 资助金额:
    $ 32.81万
  • 项目类别:
Engineering Nanoscale Aptamer-based Biomaterials that Target Cellular Receptors
针对细胞受体的工程纳米适体生物材料
  • 批准号:
    9112133
  • 财政年份:
    2015
  • 资助金额:
    $ 32.81万
  • 项目类别:
Optogenetic Characterization and Control of Stem Cell Signaling
干细胞信号传导的光遗传学表征和控制
  • 批准号:
    8674874
  • 财政年份:
    2014
  • 资助金额:
    $ 32.81万
  • 项目类别:
Multivalent Ligands to Control Stem Cell Fate
控制干细胞命运的多价配体
  • 批准号:
    8762257
  • 财政年份:
    2014
  • 资助金额:
    $ 32.81万
  • 项目类别:
Optogenetic Characterization and Control of Stem Cell Signaling
干细胞信号传导的光遗传学表征和控制
  • 批准号:
    9208064
  • 财政年份:
    2014
  • 资助金额:
    $ 32.81万
  • 项目类别:
Optogenetic Characterization and Control of Stem Cell Signaling
干细胞信号传导的光遗传学表征和控制
  • 批准号:
    9000181
  • 财政年份:
    2014
  • 资助金额:
    $ 32.81万
  • 项目类别:
Engineering Nanoscale Aptamer-based Biomaterials that Target Cellular Receptors
针对细胞受体的工程纳米适体生物材料
  • 批准号:
    8523855
  • 财政年份:
    2012
  • 资助金额:
    $ 32.81万
  • 项目类别:
Engineering Nanoscale Aptamer-based Biomaterials that Target Cellular Receptors
针对细胞受体的工程纳米适体生物材料
  • 批准号:
    8345177
  • 财政年份:
    2012
  • 资助金额:
    $ 32.81万
  • 项目类别:
Engineering Nanoscale Aptamer-based Biomaterials that Target Cellular Receptors
针对细胞受体的工程纳米适体生物材料
  • 批准号:
    8711082
  • 财政年份:
    2012
  • 资助金额:
    $ 32.81万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 32.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 32.81万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 32.81万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 32.81万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 32.81万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 32.81万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 32.81万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 32.81万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 32.81万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 32.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了